Letro-Exem Mix Liquid

Description

Overview of Letro-Exem

Letro-Exem Mix Liquid is an investigational research formulation containing two compounds commonly studied in biochemical and pharmacological research related to aromatase enzyme modulation: letrozole and exemestane.

Both compounds belong to the class of aromatase inhibitors, which are investigated in experimental systems for their interactions with the aromatase enzyme (CYP19A1), a cytochrome P450 enzyme involved in the biosynthesis of estrogens from androgen precursors.

In laboratory research settings, these compounds are often studied individually and in combination to examine enzyme inhibition dynamics, structure–activity relationships, and steroidogenic pathway regulation in cellular models.

Letrozole is classified as a non-steroidal aromatase inhibitor, whereas exemestane is a steroidal aromatase inactivator. Because these compounds interact with the aromatase enzyme through distinct molecular mechanisms, research models sometimes examine them together to evaluate comparative enzyme binding and inhibition characteristics.

Investigational research involving these compounds typically focuses on aromatase inhibition kinetics, endocrine signaling pathway modulation, and biochemical responses within steroidogenesis pathways under controlled laboratory conditions.

Chemical and Molecular Properties

Letrozole
CAS Number	107868-30-4
Molar Mass	296.410 g/mol
Chemical Structure	C17H11N5
IUPAC Name	4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
Exemestane
CAS Number	112809-51-5
Molar Mass	285.310 g/mol
Chemical Structure	C20H24O2
IUPAC Name	(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione

Working Mechanism of Letro-Exem

Both compounds in the Letro-Exem Mix are investigated for their interactions with aromatase (CYP19A1), an enzyme responsible for catalyzing the conversion of androgens into estrogenic compounds within steroidogenic biochemical pathways.

Letrozole Mechanism

Letrozole functions as a reversible non-steroidal inhibitor of aromatase. In molecular research systems, it binds competitively to the heme component of the CYP19A1 enzyme complex, inhibiting the catalytic conversion of androgen substrates into estrogenic products.

In vitro investigations have examined how this interaction influences enzyme kinetics, substrate affinity, and catalytic activity within steroidogenic pathways.

Exemestane Mechanism

Exemestane is characterized as a steroidal aromatase inactivator. Its molecular structure resembles endogenous steroid substrates, allowing it to interact with the aromatase enzyme’s active site.

In experimental systems, exemestane undergoes enzymatic processing that results in irreversible inactivation of aromatase, a mechanism sometimes described as suicide inhibition. This process involves the compound forming a covalent interaction with the enzyme following catalytic activation.

Research Applications of Letro-Exem in Laboratory Settings

Steroidogenesis Pathway Research

Experimental models investigating steroid hormone biosynthesis pathways may use aromatase inhibitors to evaluate molecular interactions within endocrine signaling networks.

Structure-Activity Relationship (SAR) Investigations

Comparative research may analyze how structural differences between steroidal and non-steroidal aromatase inhibitors influence binding affinity and enzymatic inhibition mechanisms.

Cellular Signaling Studies

Cell-based experimental models may investigate how inhibition of aromatase influences downstream signaling pathways, gene expression patterns, and intracellular biochemical responses.

Why Choose Purerawz for Letro-Exem?

Buy Letro Exem for laboratory research use from our online shop. At Purerawz, we provide high-quality reference materials. Each research compound comes with a Certificate of Analysis for verification of purity and concentration.

Disclaimer

This information is for educational purposes only and not medical advice. Products are for research use only. Research must follow IRB or IACUC guidelines. Verify information independently before purchasing. By ordering, you agree to our Terms and Conditions. If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co

Reference Links

•  Group, B. 1. C. (2009). Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. New England Journal of Medicine, 361(8), 766-776. https://doi.org/10.1056/nejmoa0810818
• Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Dieras, V., & Slamon, D. J. (2016). Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine, 375(20), 1925-1936. https://doi.org/10.1056/nejmoa1607303
• Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., Coates, A. S., Bajetta, E., Dodwell, D., Coleman, R. E., Fallowfield, L. J., Mickiewicz, E., Andersen, J., Lønning, P. E., Cocconi, G., . . . Bliss, J. M. (2004). A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. New England Journal of Medicine, 350(11), 1081-1092. https://doi.org/10.1056/nejmoa040331